TENECTEPLASE

作品数：19被引量：36H指数：3
导出分析报告
相关作者：具星爱更多>>
相关机构：中国医科大学更多>>
相关期刊：《德国临床用药》《Chinese Medical Journal》《World Journal of Emergency Medicine》《国外药讯》更多>>
相关基金：国家自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Intravenous tenecteplase compared with alteplase for minor ischaemic stroke:a secondary analysis of the AcT randomised clinical trial
《Stroke & Vascular Neurology》2024年第6期604-612,共9页Radhika Nair Nishita Singh Mahesh Kate Negar Asdaghi Robert Sarmiento Fouzi Bala Shelagh B Coutts MacKenzie Horn Alexandre Y Poppe Heather Williams Ayoola Ademola Ibrahim Alhabli Faysal Benali Houman Khosravani Gary Hunter Aleksander Tkach Herbert Alejandro Manosalva Alzate Aleksandra Pikula Thalia Field Anurag Trivedi Dar Dowlatshahi Luciana Catanese Ashfaq Shuaib Andrew Demchuk Tolulope Sajobi Mohammed A Almekhlafi Richard H Swartz Bijoy Menon Brian H Buck 
Background In ischaemic stroke,minor deficits(National Institutes of Health Stroke Scale(NIHSS)≤5)at presentation are common but often progress,leaving patients with significant disability.We compared the efficacy an...
关键词：ACUTE MINOR analysis 
Outcomes associated to the time to treatment with intravenous tenecteplase for acute ischaemic stroke:subgroup analysis of the TRACE-2 randomised controlled clinical trial
《Stroke & Vascular Neurology》2024年第6期613-622,共10页Shuya Li Runqi Wangqin Yuesong Pan Aoming Jin Hao Li Lee H Schwamm Marc Fisher Bruce C V Campbell Mark W Parsons Ziran Wang Hongguo Dai Deyang Li Runhui Li Junhai Wang David Wang Yilong Wang Xingquan Zhao Zixiao Li Huaguang Zheng Yunyun Xiong Xia Meng Yongjun Wang 
National Natural Science Foundation of China(81870905,U20A20358,82111530203);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M 5-029);The National Science and Technology Major Project(2017ZX09304018).
Background The benefit of intravenous alteplase in acute ischaemic stroke(AIS)is time-dependent.Tenecteplase is non-inferior to alteplase among patients with AIS.We aimed to delineate the association of the stroke ons...
关键词：INTRAVENOUS clinical treatment 
Bleeding characteristics and mortality outcomes following ST-elevation myocardial infarction thrombolysis:a 5-year analysis in an Asian population
《World Journal of Emergency Medicine》2024年第6期433-440,共8页Hock Peng Koh Jivanraj RNagarajah Hasnita Hassan Noel Thomas Ross 
BACKGROUND:Bleeding outcomes are crucial primary safety endpoints in studies involving thrombolytic agents.This study aimed to determine the incidence,characteristics and mortality outcomes of bleeding following ST-el...
关键词：BLEEDING ST-elevation myocardial infarction thrombolysis ASIAN TENECTEPLASE STREPTOKINASE 
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke TenecteplaseⅡ(CHABLIS-TⅡ):rationale and design
《Stroke & Vascular Neurology》2024年第6期708-714,共7页Xin Cheng Lan Hong Longting Lin Leonid Churilov Yifeng Ling Yiran Zhang Lumeng Yang Mark Parsons Qiang Dong 
Background and purpose Tenecteplase(TNK)has demonstrated non-inferiority to alteplase in patients who had an acute ischaemic stroke presenting within 4.5 hours from symptom onset.The trial is aimed to explore the effi...
关键词：RATIONAL SELECTION CENTRE 
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection:the umbrella phase IIa CHABLIS-T randomised clinical trial被引量：3
《Stroke & Vascular Neurology》2024年第5期551-559,共9页Xin Cheng Lan Hong Leonid Churilov Longting Lin Yifeng Ling Jin Zhang Jianhong Yang Yu Geng Danhong Wu Xueyuan Liu Xiaoyu Zhou Yuwu Zhao Qijin Zhai Liandong Zhao Yangmei Chen Ying Guo Xiaofei Yu Fan Gong Yi Sui Gang Li Lumeng Yang Hong-Qiu Gu Yilong Wang Mark Parsons Qiang Dong the CHABLIS-T collaborators 
National Key R&D Program of China(2017YFC1308201);Clinical Research Plan of SHDC(SHDC2020CR1041B);Shanghai Municipal Key Clinical Specialty(shslczdzk06102).
Background The performance of intravenous tenecteplase in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown. We investigated th...
关键词：doses THROMBOLYSIS random 
Tenecteplase versus alteplase for acute ischaemic stroke:a meta-analysis of phaseⅢrandomised trials
《Stroke & Vascular Neurology》2024年第4期360-366,I0001-I0021,共28页Yunyun Xiong Liyuan Wang Guangshuo Li Kai-Xuan Yang Manjun Hao Shuya Li Yuesong Pan Yongjun Wang 
supported by grants from The National Natural Science Foundation(82171272);Beijing Municipal Science and Technology Committee(Z211100003521019);Beijing Hospitals Authority(PX2022019).
Background Tenecteplase(TNK)was found non-inferior to alteplase in recent clinical trials.We aimed to elucidate the efficacy and safety of TNK versus alteplase for acute ischaemic stroke(AIS).Methods Systematic litera...
关键词：analysis RANDOM PHASE 
Intra-arterial tenecteplase during thrombectomy for acute stroke(BRETIS-TNK II):rationale and design被引量：1
《Stroke & Vascular Neurology》2024年第1期59-65,共7页Zi-Ai Zhao Jing Qiu Wei Li Thanh Nguyen Shouchun Wang Huaizhang Shi Ming Wei Feng Wang Di Li Hui-Sheng Chen 
supported by grants from the Science and Technology Project Plan of Liao Ning Province(2022JH2/101500020);the Science and Technology Plan of Shen Yang(20-205-4-007).
Background Our recent pilot study suggests intra-arterial tenecteplase(TNK)during the first pass of endovascular treatment(EVT)seems safe,may increase first-pass reperfusion and good outcome in acute ischaemic stroke(...
关键词：rational STRATIFIED TNK 
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open- label, controlled trial被引量：2
《Stroke & Vascular Neurology》2024年第1期82-89,共8页Yunyun Xiong Bruce C V Campbell Marc Fisher Lee H Schwamm Mark Parsons Hao Li Yuesong Pan Xia Meng Xingquan Zhao Yongjun Wang 
supported by the National Natural Science Foundation of China(81870905,82171272);Beijing Municipal Science&Technology Committee(Z211100003521019);Beijing Hospitals Authority(PX2022019).
Background and purpose Recombinant human TNK tissue-type plasminogen activator(rhTNK-tPA)was not inferior to alteplase for ischaemic stroke within 4.5hours.Our study aimed to investigate the efficacy and safety of rhT...
关键词：Therapy random Rational 
Tenecteplase versus alteplase in treatment of acute ST-segment elevation myocardial infarction:A randomized non-inferiority trial被引量：4
《Chinese Medical Journal》2024年第3期312-319,共8页Xingshan Zhao Yidan Zhu Zheng Zhang Guizhou Tao Haiyan Xu Guanchang Cheng Wen Gao Liping Ma Liping Qi Xiaoyan Yan Haibo Wang Qingde Xia Yuwang Yang Wanke Li Juwen Rong Limei Wang Yutian Ding Qiang Guo Wanjun Dang Chen Yao Qin Yang Runlin Gao Yangfeng Wu Shubin Qiao 
supported by the Guangzhou Recomgen Biotech Co.,Ltd.The funder had no role in the design and conduct of the study;collection,management,analysis,and interpretation of the data
Background:A phase II trial on recombinant human tenecteplase tissue-type plasminogen activator(rhTNK-tPA)has previously shown its preliminary efficacy in ST elevation myocardial infarction(STEMI)patients.This study w...
关键词：Thrombolytic therapy rhTNK-tPA Randomized controlled trial ST elevation myocardial infarction 
Is tenecteplase ready to replace alteplase to treat acute ischaemic stroke? The knowns and unknowns被引量：3
《Stroke & Vascular Neurology》2022年第1期1-5,共5页Yi Dong Yi Sui Xin Cheng David Z Wang 
Tenecteplase(TNKase,TNK-tPA or TNK)is a thrombolytic agent derived from the tissue plasminogen activator(tPA).It is a 527-amino acid glycoprotein developed by replacing three amino acids at the T,N and K positions of ...
关键词：TECHNOLOGY replace replacing 
全选清除导出
共2页<12>
检索报告 对象比较 聚类工具 使用帮助 返回顶部